Speed up the ECG screening process with KardiaStation
Prescribing and managing QT-prolonging medications just got easier
The Problem
Many commonly prescribed medications cause QT prolongation
A prolonged QT interval may lead to a dangerously fast rhythm, Torsades de Pointe, which is a potentially fatal polymorphic ventricular tachycardia (VT).
To assess the risk associated with long QT, the FDA requires a baseline ECG when prescribing or titrating some QT-prolonging medications. This requirement may present a barrier to physicians and patients to be able to start treatment without delay.
~3% of prescriptions worldwide are for QT prolonging medications³
Concomitant administration of QT prolonging medications can increase risk of Torsade’s de Pointes³
Torsade's de Pointes (TdP) may be more common than we think
Prolonged QT interval is associated with a 3x increase in risk of sudden cardiac death (SCD) over 6.7 years⁴
2–3 weeks
treatment delay can occur when referring for an ECG
250+ medicines
prolong heart QT intervals¹
"There is no absolute QTc interval at which a psychotropic should not be used, rather a comprehensive risk-benefit analysis should include an assessment of pharmacologic and non-pharmacologic risks for TdP versus the risk of failure to control high-risk psychopathology or of psychiatric decompensation."
American Psychiatric Association (APA) RESOURCE Document on QTc Prolongation & PSYCHOTROPIC Medications (2018)
Standard QT Screening Process
QT screening can create barriers along the clinical care pathway
- Patient leaves to get an ECGTreatment is delayedOffice must follow up for resultsTreatment options may be limited
- Inconvenience of extra visit for ECGPotential for additional costsPossible lack of follow-upMay miss out on optimal care
Practice Impacts
- Patient leaves to get an ECG
- Treatment is delayed
- Office must follow up for results
- Treatment options may be limited
Patient Impacts
- Inconvenience of extra visit for ECG
- Potential for additional costs
- Possible lack of follow-up
- May miss out on optimal care
The Solution
KardiaStation can dramatically simplify the process of prescribing QT-prolonging medications
KardiaStation delivers a robust solution to the problem of prescribing medications that are known to cause QT prolongation.
The service is comprised of three integrated technologies that seamlessly work together to provide you with a faster, easier process for performing an ECG in-office before prescribing or titrating these medications.
KardiaMobile® 6L
#1 doctor-recommended personal ECG brand
KardiaStation App
Connects with KardiaMobile 6L for accurate QT readings
KardiaPro® Portal
Track, manage and document patient results
Prescribing Process with Kardiastation*
Streamlined, accurate QT screening can benefit your practice
- kardiaStation.prescribing.list.one.text
- kardiaStation.prescribing.list.two.text
- kardiaStation.prescribing.list.three.text
Record ECGs in 30 Seconds
The easy-to-use, FDA-cleared KardiaMobile 6L device allows you to quickly capture an ECG.
Validated QT Measurements
Leveraging advanced FDA-cleared algorithm to inform your treatment selection.
Easy Workflow Integration
Data is securely stored and fits into existing practice workflow through KardiaPro web-based portal or integration options with EHR, SDK, or API
Trusted Results
Results that help you prescribe with confidence
KardiaStation delivers a streamlined way to screen for QT prolongation that is grounded in proven results.
- The six leads of KardiaMobile 6L are equivalent to the same six leads from a gold standard 12-lead ECG⁵
- KardiaMobile 6L is able to detect Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with SVE, Sinus Rhythm with PVCs and Sinus Rhythm with Wide QRS†
- Kardia personal ECG devices are used by the world's leading cardiologists
Accurate QT Measurements
Instantly displays accurate QT interval measurements
Faster Screening
Capture a medical-grade ECG in just 30 seconds
Easily integrated into existing visit
FDA-cleared determinations of the 6 most common arrhythmias
Easier ECG Process
No patient prep time or adhesives are needed
Instant, actionable data to help you make faster clinical decisions
KardiaMobile® 6L
6-lead personal ECG device
- #1 patient-preferred and doctor-recommended personal ECG brand
- Records an ECG in 30 seconds
KardiaStation
Clinician-facing app
- Includes accurate QT measurements
- FDA-cleared algorithms to detect common arrhythmias
- Available on iOS and Android
KardiaPro®
Web portal to access ECGs
- Access QT readings 24/7
- Easy documentation and patient management
- HIPAA compliant, SOC-2 certified
Get started with KardiaStation.
With AliveCor's portfolio of flexible subscription plans, incorporating KardiaStation into your practice is easy.
Legal & References
* AliveCor makes no guarantee, promise, or direct instruction regarding billing, coverage, or reimbursement. Accurate coding and claims submission practices are the sole responsibility of the health care provider.† KardiaMobile 6L does not check for heart attack.
- Woosley RL, Heise CW, Gallo T, Woosley D and Romero KA, www.CredibleMeds.org, QTdrugs List, September 13, 2023.
- Das B, et al. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medication sand related drug-drug interactions in a cohort of psychiatry patients. Therapies (2019).
- Swenson RS, et al. Prolonged QT Interval in Patients Receiving Psychotropic Medications. Journal of the American Psychiatric Nurses Association. 2020;26(4):344-353.
- Funk MC, et al. Resource Document on GTc Prolongation and Psychotropic Medications. American Psychiatric Association (APA) Reference Document. Approved June 2018.
- Azram M, et al., Clinical validation and evaluation of a novel six-lead handheld electrocardiogram recorder compared to the 12-lead electrocardiogram in unselected cardiology patients (EVALECG Cardio), European Heart Journal — Digital Health, Volume 2, Issue 4, December 2021.
- Hnatkova K, et al. Precision of QT interval measurement by advanced electrocardiographic equipment. Pacing Clin Electrophysiol. 2096;29(11): 1277-84.